Skip to content

Spyre Therapeutics

US · SYRE #1646 by market cap Listed 1970
93.47 -4.16 -4.26%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Recent news

  • Rating change
    A Quick Look at Today's Ratings for Spyre Therapeutics(SYRE.US), With a Forecast Between $116 to $130
    Market Newswire · 2026/8/27
  • J.P. Morgan Initiates Spyre Therapeutics(SYRE.US) With Buy Rating, Announces Target Price $116
    Market Newswire · 2026/11/13
  • Rating change
    JonesTrading Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Raises Target Price to $140
    Market Newswire · 2026/8/13
  • Rating change
    BTIG Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $121
    Market Newswire · 2026/10/20
  • Rating change
    Stifel Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $123
    Market Newswire · 2026/8/14
  • Rating change
    Citi Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $119
    Market Newswire · 2026/10/21
  • Rating change
    LifeSci Capital Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $129
    Market Newswire · 2026/8/15
  • Rating change
    Jefferies Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Raises Target Price to $126
    Market Newswire · 2026/9/9
  • Wedbush Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $123
    Market Newswire · 2026/10/20
  • Rating change
    JonesTrading Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Raises Target Price to $130
    Market Newswire · 2026/10/1
  • Rating change
    Citi Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Raises Target Price to $119
    Market Newswire · 2026/10/20
  • Rating change
    A Quick Look at Today's Ratings for Spyre Therapeutics(SYRE.US), With a Forecast Between $115 to $127
    Market Newswire · 2026/8/26
  • Rating change
    JonesTrading Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $121
    Market Newswire · 2026/9/28
  • UBS Initiates Spyre Therapeutics(SYRE.US) With Buy Rating, Announces Target Price $120
    Market Newswire · 2026/10/12
  • Rating change
    Leerink Partners Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Raises Target Price to $128
    Market Newswire · 2026/9/9
  • Wells Fargo Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $115
    Market Newswire · 2026/11/6
  • Rating change
    J.P. Morgan Initiates Spyre Therapeutics(SYRE.US) With Buy Rating, Announces Target Price $110
    Market Newswire · 2026/10/1
  • Rating change
    LifeSci Capital Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $116
    Market Newswire · 2026/9/9
  • A Quick Look at Today's Ratings for Spyre Therapeutics(SYRE.US), With a Forecast Between $115 to $131
    Market Newswire · 2026/11/5
  • Rating change
    Guggenheim Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $130
    Market Newswire · 2026/8/27
  • Rating change
    Wells Fargo Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $115
    Market Newswire · 2026/10/4
  • Rating change
    LifeSci Capital Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Raises Target Price to $129
    Market Newswire · 2026/8/11
  • Rating change
    Wedbush Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $130
    Market Newswire · 2026/8/11
  • Rating change
    BTIG Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Raises Target Price to $132
    Market Newswire · 2026/8/11
  • Rating change
    LifeSci Capital Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Raises Target Price to $128
    Market Newswire · 2026/8/8

Headlines are aggregated automatically and are not independently verified or edited by our team.

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

Spyre Therapeutics discussion 0 comments

Add a comment